Cyclophilin A (Cyp A) binds the human immunodeficiency virus type 1 (HIV-1) capsid (CA) protein and contributes to the early events in virus replication in some cells. The retroviral restriction factor TRIM5α can inhibit the early, post-entry phase of infection by associating with the incoming viral capsid. Cyp A has been proposed to prevent restriction factor binding in human cells, thus enhancing HIV-1 infectivity, and to potentiate restriction of HIV-1 in monkey cells. Here we show that the positive effects of Cyp A-CA binding on HIV-1 infectivity do not depend on human TRIM5α. Disruption of Cyp A binding to CA partially relieved the block to HIV-1 infection imposed by several TRIM5α variants, but Cyp A-CA binding was not absolutely required for TRIM5α antiviral activity. Inhibition of Cyp A function by cyclosporine significantly decreased the efficiency of TRIM5α-mediated restriction only when the restricted virus capsid interacted with Cyp A.
Introduction
The immunophilin cyclophilin A (Cyp A) binds to a flexible, proline rich loop in the N-terminal domain of the human immunodeficiency virus type 1 (HIV-1) capsid (CA) and contributes to the efficient infection of some human cells (Braaten and Luban, 2001; Franke et al., 1994; Gamble et al., 1996; Gitti et al., 1996; Luban et al., 1993; Thali et al., 1994) . Cyp A is a cytosolic, ubiquitously expressed enzyme that can catalyze the cis/trans-isomerization of prolyl peptide bonds (Fischer et al., 1984 (Fischer et al., , 1989 Galat, 2003) . Cyp A binds glycine 89-proline 90 in the HIV-1 CA, and changes in these residues that disrupt Cyp A association cause a significant decrease in the efficiency of HIV-1 replication in some human cells (Braaten and Luban, 2001; Braaten et al., 1996b) . The interaction between the HIV-1 CA and Cyp A can also be disrupted by cyclosporine A (CsA), an immunosuppressive drug that competitively binds to the Cyp A active site (Braaten et al., 1996a; Luban et al., 1993) . Capsids from some retroviruses, such as simian immunodeficiency virus (SIV mac ) and the gammaretrovirus murine leukemia virus (MLV), do not bind Cyp A; Cyp A expression in the host cell is not necessary for successful infection by these viruses (Franke et al., 1994; Thali et al., 1994) .
The role of Cyp A during HIV-1 infection remains to be fully elucidated. Cyp A is necessary for an early, post-entry step in the target cell (Braaten et al., 1996b; Sokolskaja et al., 2004) . Preventing the binding of Cyp A to the HIV-1 CA protein, either by treatment of virions with CsA or by altering CA to abolish Cyp A binding, leads to defects in the accumulation of reverse transcripts (Braaten et al., 1996b) . Some reports have suggested that Cyp A facilitates the disassembly of the HIV-1 capsid complex by catalyzing the cis/trans-isomerization of the gly 89-pro 90 peptide bond (Bosco and Kern, 2004; Bosco et al., 2002; Howard et al., 2003) . Others have suggested that Cyp A protects the HIV-1 capsid from an antiviral activity in human cells Sokolskaja et al., 2004; Towers et al., 2003) .
The species-specific tropism of a particular retrovirus can be determined by dominant host factors that recognize the incoming capsid (Bieniasz, 2004; Goff, 2004) . One of these factors, TRIM5α, restricts HIV-1 infection in Old World monkey cells . The TRIM5 gene encodes at least three isoforms; the longest isoform, TRIM5α, is the only one that possesses a C-terminal B30.2 domain and exhibits antiviral activity (Hatziioannou et al., 2004b; Keckesova et al., 2004; Perron et al., 2004; Stremlau et al., 2004; Yap et al., 2004) . Variation in TRIM5α protein sequences among different primate species accounts for the observed patterns of speciesspecific restrictions to retrovirus infections (Song et al., 2005a (Song et al., , 2005b . For example, rhesus monkey TRIM5α (TRIM5α rh ), an Old World monkey TRIM5α protein, potently blocks HIV-1 but only modestly restricts SIV mac . In contrast, TRIM5α proteins from New World monkeys restrict SIV mac but not HIV-1 (Song et al., 2005a (Song et al., , 2005b . One exceptional New World monkey, the owl monkey, expresses a TRIM5α-Cyp A fusion protein (TRIMCyp) that inhibits infection by HIV-1 . The block to HIV-1 in these cells can be overcome by changes in the HIV-1 CA protein that abolish Cyp A binding or by treatment of the target cell with CsA Towers et al., 2003) .
Human TRIM5α (TRIM5α hu ) fails to restrict SIV mac but partially inhibits HIV-1 (Hatziioannou et al., 2004b; Keckesova et al., 2004; Stremlau et al., 2004; Yap et al., 2004) . However, expression of TRIM5α hu potently inhibits infection by N-tropic MLV (N-MLV) (Hatziioannou et al., 2004b; Keckesova et al., 2004; Perron et al., 2004; Stremlau et al., 2004; Yap et al., 2004) . The determinants of antiviral potency in TRIM5α hu have been mapped to the B30.2 domain (Nakayama et al., 2005; Perez-Caballero et al., 2005; Sawyer et al., 2005; Yap et al., 2005) . A single amino acid change in TRIM5α hu , R332P, increases the anti-HIV-1 activity to a level comparable to that of TRIM5α rh Yap et al., 2005) . Surprisingly, this change also confers the ability on TRIM5α hu to restrict SIV mac .
The viral determinants for restriction map to CA, suggesting that TRIM5α associates either directly or indirectly with CA Kootstra et al., 2003; Munk et al., 2002; Owens et al., 2003; Stevens et al., 2004) . Changes in the Cyp A-binding loop of the HIV-1 CA can allow partial escape from TRIM5α (Kootstra et al., 2003; Hatziioannou et al., 2004a; Owens et al., 2004) ; however, at least one report has shown that an alteration of glycine 89 in CA does not lead to any enhancement of HIV-1 infection in a rhesus monkey kidney cell line . Recently, TRIM5α proteins from Old World monkeys have been shown to bind specifically to assembled HIV-1 capsid complexes; expression of a restricting TRIM5α protein in otherwise susceptible cells is associated with the accelerated disassembly of the capsid of the restricted virus (Stremlau et al., in press ).
To date, cofactors necessary for TRIM5α antiviral activity have not been reported. The involvement of Cyp A and TRIM5α during early, post-entry events in retroviral infection suggests that their activity may be linked. Both TRIM5α and Cyp A associate with the HIV-1 CA, and reverse transcripts fail to accumulate in either TRIM5α-restricted cells or in some human cells where the interaction between Cyp A and CA has been disrupted (Besnier et al., 2002; Braaten et al., 1996b; Hatziioannou et al., 2003; Munk et al., 2002; Perron et al., 2004; Stremlau et al., 2004) . It has been suggested that the positive effects of Cyp A on HIV-1 infection in human cells are a consequence of Cyp A blocking the binding of the TRIM5α hu restriction factor to the HIV-1 capsid Sokolskaja et al., 2004) . In contrast to the generally positive effects of Cyp A on HIV-1 replication in human cells, disrupting Cyp A-CA binding results in increased HIV-1 infectivity in some monkey cells; indirect evidence suggests that TRIM5-like restriction factors may be involved in this effect Owens et al., 2004; Towers et al., 2003) . It has even been suggested that Cyp A might be required for TRIM5α-mediated resistance to HIV-1 infection in Old World monkey cells (Berthoux et al., 2005) . Here we examine possible connections between Cyp A and TRIM5α. We investigate the restriction activity of TRIM5α variants in settings where Cyp A-capsid interaction is prevented or does not occur. We also examined effects of Cyp binding on HIV-1 infection in cells that express or lack TRIM5α hu .
Results and discussion

Effects of cyclosporine A (CsA) treatment on TRIM5α antiviral potency
CsA is an 11-amino acid cyclic peptide that competitively inhibits the interaction between Cyp A and the HIV-1 CA (Franke et al., 1994; Thali et al., 1994) . We used CsA to test the requirement for Cyp A in HIV-1 restriction by TRIM5α. Human cells that stably express TRIM5α rh or control cells transduced with the empty pLPCX vector were treated with CsA and incubated with a VSV G-pseudotyped HIV-1-GFP vector (HIV-1-GFP). CsA treatment of the control cells did not significantly affect the efficiency of HIV-1-GFP infection in these cells compared to that seen in untreated cells (Fig. 1A ). This result was consistent with previous findings Owens et al., 2004) . In contrast, CsA treatment of TRIM5α rhexpressing cells enhanced HIV-1-GFP infection compared to that seen in untreated cells expressing TRIM5α rh (Fig. 1A) . The partial relief of HIV-1 restriction in TRIM5α rh cells was more obvious when HIV-1-GFP infection was carried out at a high multiplicity of infection (m.o.i.) ( Fig. 1A) . Thus, Cyp A can enhance the TRIM5α rh -mediated block to HIV-1 infection; however, TRIM5α rh can still restrict HIV-1 infection even when the interaction between Cyp A and CA is blocked by CsA.
The HIV-1 restricting activities of some TRIM5α variants depend strongly on Cyp A HeLa cells that stably overexpress TRIM5α hu exhibit a modest restriction of HIV-1 infection (Hatziioannou et al., 2004b; Stremlau et al., 2004; Yap et al., 2004) . The determinants of HIV-1 antiviral potency have been mapped to the B30.2 domain of TRIM5α Stremlau et al., 2005; Yap et al., 2005) . Replacing residues 323-332 in TRIM5α hu with the corresponding sequence from TRIM5α rh generates a chimeric protein, H(R323-332), that possesses anti-HIV-1 potency that is nearly equivalent to that of wild-type TRIM5α rh . Two single amino acid changes in the B30.2 domain of TRIM5α hu , K324N and R332P, also dramatically enhance the ability of TRIM5α hu to restrict HIV-1 Yap et al., 2005) . Using CsA, we assessed the role of Cyp A in HIV-1 restriction in human cells expressing wild-type TRIM5α hu or the three TRIM5α variants described above. As previously reported , CsA treatment of HeLa cells stably expressing TRIM5α hu did not significantly increase or decrease the level of HIV-1-GFP infection compared to that seen in untreated cells ( Fig. 1A) . However, the antiviral potency of each of the TRIM5α variants was significantly diminished in the presence of CsA, particularly when the cells were challenged at a higher m.o.i. Thus, the TRIM5α variants exhibit a stronger dependence on Cyp A for efficient HIV-1 restriction than wildtype TRIM5α rh .
TRIM5α restriction of SIV mac does not depend on Cyp A
Cyp A does not bind to the SIV mac CA protein and SIV mac replication is not affected by CsA treatment (Braaten et al., 1996c; Bukovsky et al., 1997; Franke et al., 1994; Thali et al., 1994) . Neither TRIM5α rh nor TRIM5α hu potently restrict SIV mac Fig. 1 . Cyclosporine A (CsA) partially abrogates TRIM5α-mediated restriction of HIV-1. (A) HeLa cells were transduced with an empty control vector or vectors expressing wild-type TRIM5α rh , wild-type TRIM5α hu , the TRIM5α hu mutants K324N and R332P, or the human/rhesus TRIM5α chimera H(R323-332). The cells were incubated for 2 h in the presence of 0.1% ethanol or 5 μM CsA and then either 4 kcpm or 16 kcpm RT units of HIV-1-GFP were added. (B) The experiment was carried out as described in panel A except that either 1 kcpm or 8 kcpm RT units of SIV mac -GFP were added to the cells. (C) TE671 cells were incubated for 2 h with 0.1% EtOH or 5 μM CsA before the addition of either N-MLV, B-MLV, or NB-MLV vectors expressing GFP at various dilutions. The percentage of GFP-positive cells was determined by FACS. The experiment was repeated with similar results. infection . We treated cells that express TRIM5α rh , TRIM5α hu , K324N, R332P, or H(R323-332) with CsA and then challenged them with SIV mac -GFP. We observed a slight enhancement of SIV mac infection after CsA treatment in all the cell lines tested, including cells expressing TRIM5α hu R332P (Fig. 1B) . Even at a high m.o.i. of SIV mac infection, the addition of CsA to cells stably expressing R332P did not significantly relieve the restriction. Apparently, Cyp A enhances the antiviral potency of TRIM5α R332P in a manner dependent on the targeted virus. One viral property potentially relevant to this effect is the ability of the viral capsid to bind Cyp A.
We observed no effect of CsA treatment on the TRIM5α humediated restriction of N-MLV, which does not interact with Cyp A. Human TE671 cells restrict N-MLV but not B-MLV or the dual-tropic NB-MLV (Hatziioannou et al., 2004b; Towers et al., 2000 Towers et al., , 2003 . N-MLV restriction in TE671 cells was not relieved by the addition of CsA (Fig. 1C ). This result is consistent with the possibility that Cyp A must interact with the viral capsid to enhance TRIM5α-mediated restriction.
Effects of CsA treatment on different TRIM5α species variants
In general, TRIM5α variants from Old World monkey cells potently restrict HIV-1 but not SIV mac infection; New World monkey TRIM5α variants potently restrict SIV mac but not HIV-1 infection (Song et al., 2005a (Song et al., , 2005b . Two exceptions are a TRIM5/Cyclophilin A fusion protein (TRIM-Cyp) from owl monkeys, a New World monkey species, that restricts HIV-1, and TRIM5α from spider monkeys (TRIM5α sp ), another New World monkey, that restricts both HIV-1 and SIV mac Song et al., 2005b) . To investigate further the role of Cyp A in TRIM5α restriction, we treated human cells that stably express various Old World and New World monkey TRIM5α variants with CsA and infected them with HIV-1 or SIV mac . HIV-1 restriction in non-permissive cells could be partially relieved by CsA treatment regardless of the species origin of the restricting TRIM5α variant (Fig. 2) ; for example, the block to HIV-1 infection resulting from the expression of TRIM5α rh , TRIM5α AGM(pyg) , TRIM5α AGM(tan) , or TRIM5α sp was partially relieved by CsA treatment. SIV mac infection, even in the control cells expressing the empty pLPCX vector, exhibited a 2-3-fold increase in efficiency after CsA treatments (Fig. 2) . However, SIV mac restriction by TRIM5α AGM(tan) , TRIM5α sq , or TRIM5α sp was not specifically affected by the presence of CsA (Fig. 2) . These observations provide further support for Cyp A enhancement of the restriction of HIV-1 but not SIV mac infection by TRIM5α variants. The data are consistent with the enhancement of TRIM5α restriction by Cyp A being dependent upon the interaction of Cyp A and the restricted viral capsid.
Effects of CA mutations that abolish Cyp A binding on HIV-1 restriction
Residues 89 and 90 on the HIV-1 CA make direct contacts with Cyp A (Gamble et al., 1996) . Previous studies have shown that changing the glycine at position 89 to an alanine (G89A) decreases the affinity of the interaction between CA and Cyp A and leads to a significant decrease in HIV-1 infectivity in some human cells (Braaten et al., 1996a; Franke and Luban, 1996; Franke et al., 1994) . However, this G89A mutant, which is not restricted by TRIM-Cyp, can efficiently infect owl monkey cells Towers et al., 2003) . Some previous reports have shown that the G89A mutant can partially escape restriction in Old World monkey cells (Hatziioannou et al., 2004a; Owens et al., 2004) ; however, in some Old World monkey cells, G89A still exhibited a low level of infection . We examined the infection of HeLa cells expressing TRIM5α variants by wild-type and G89A HIV-1 in the presence or absence of CsA (Fig. 3) . The G89A mutant was inhibited by TRIM5α rh and other TRIM5α variants, even after CsA treatment. Thus, TRIM5α retains the ability to restrict HIV-1 viruses that do not bind Cyp A. The G89A mutant was slightly less sensitive to restriction by several of the TRIM5α variants than the wild-type HIV-1, particularly considering the lower basal level of G89A infectivity in the control cells. The relief of restriction by CsA treatment was decreased for the G89A virus compared with that seen for wild- Fig. 2 . CsA partially relieves restriction of HIV-1 but not SIV mac by TRIM5α from different species. HeLa cells transduced with an empty control vector or vectors expressing TRIM5α rh , TRIM5α hu , TRIM5α AGM(pyg) , TRIM5α AGM(tan) , TRIM5α sq , or TRIM5α sp were incubated for 2 h in the presence of 0.1% ethanol or 5 μM CsA and then infected with HIV-1-GFP or SIV mac -GFP. The percentage of GFP-positive cells was determined by FACS. The experiment was repeated twice with comparable results. The results of a typical experiment are shown. type HIV-1. These observations are consistent with the contribution of Cyp A-CA binding to the positive effect that Cyp A exerts on TRIM5α-mediated restriction.
Role of TRIM5α in Cyp A effects on HIV-1 replication
It has been suggested that Cyp A may protect the HIV-1 capsid from TRIM5α hu . If this hypothesis is correct, then an HIV-1 virus that does not bind Cyp A should be more susceptible to restriction in cells that express TRIM5α hu than in cells that do not. To determine the effects of TRIM5α hu expression on HIV-1 infection in the absence or presence of CsA in a setting in which no endogenous TRIM5α hu is present, we transduced Cf2Th canine thymocytes with an empty control vector or with vectors expressing TRIM5α variants. Canine cells do not express a TRIM5 ortholog (Song et al., 2005a) . In empty control cells, the addition of CsA caused a slight decrease in HIV-1 infectivity (Fig. 4) . The CsA effect and the decrease in HIV-1 infectivity associated with TRIM5α hu expression were additive and apparently independent. CsA treatment caused a slight increase in the infectivity of HIV-1 in Cf2Th cells expressing TRIM5α rh . The basal level of infection was decreased for the G89A mutant compared with wild-type HIV-1. G89A did not escape restriction by TRIM5α rh in canine cells. CsA treatment had no effect on the infectivity of the G89A mutant (Fig. 4) .
The role of FK506-binding proteins in TRIM5α restriction
FK506-binding proteins (FK506BP) are also members of the immunophilin family of proteins and bind the immunosuppressant drugs FK506 and rapamycin (Davies and Sanchez, 2005) . We studied the role of FK506-binding proteins in HIV-1restricted cells using rapamycin. The levels of HIV-1-GFP Fig. 4 . The effects of CsA treatment and TRIM5α expression on HIV-1 infectivity in canine cells. Cf2Th canine cells transduced with an empty control vector or vectors expressing TRIM5α rh or TRIM5α hu were incubated for 2 h in the presence of 0.1% ethanol or 5 μM CsA and then infected with various amounts of HIV-1-GFP or the G89A mutant of HIV-1-GFP. The percentage of GFP-positive cells was determined by FACS. The results of a typical experiment of three independent experiments are shown. Fig. 3 . An HIV-1 CA mutant that does not bind Cyp A is still restricted by TRIM5α. HeLa cells transduced with an empty control vector or vectors expressing wildtype TRIM5α rh , wild-type TRIM5α hu , the TRIM5α hu mutants K324N and R332P, or the human/rhesus chimera H(R323-332) were incubated for 2 h in the presence of 0.1% ethanol or 5 μM CsA and then infected with either 14 kcpm or 56 kcpm of HIV-1-GFP or the G89A mutant HIV-1-GFP. The percentage of GFP-positive cells was determined by FACS. The experiment was repeated with similar results. infection did not change in human cells treated with rapamycin compared with those in untreated control cells (Fig. 5) . Moreover, rapamycin treatment of the cell lines expressing the TRIM5α variants did not relieve restriction in any observable way (Fig. 5) . Thus, the functions of FK506-binding proteins that are inhibitable by rapamycin play no necessary role in natural HIV-1 infection or in the TRIM5α restriction pathway.
Effects of knocking down Cyp A expression with siRNA in primary rhesus monkey cells VSV-G-pseudotyped HIV-1 does not efficiently infect primary rhesus lung (PRL) cells, which are derived from the rhesus macaque, an Old World monkey species (Hofmann et al., 1999) . We tested the requirement for Cyp A in this restriction by interfering with Cyp A expression using small interfering RNA (siRNA). Transfection of an siRNA specific for TRIM5α relieved the block to HIV-1-GFP by nearly 30fold, as previously reported . Transfection of a pool of four Cyp A-specific siRNAs partially relieved restriction in the PRL cells, resulting in an 11-fold increase in HIV-1 infectivity (Fig. 6 ). Other siRNAs that specifically targeted cyclophilin M, cyclophilin 40, FK506BP2, FK506BP4, and FK506BP5 did not enhance HIV-1 infectivity in PRL cells (Fig. 6 and data not shown) . These results are consistent with Cyp A enhancing TRIM5α rh restriction of HIV-1 infection.
Discussion
Host cell factors that modulate TRIM5α antiviral potency have not been identified. TRIM5α retains its antiviral potency in a broad range of mammalian cells, suggesting that any cofactor must be highly conserved and ubiquitously expressed (Javanbakht et al., 2005; Keckesova et al., 2004; Perez-Caballero et al., 2005; Saenz et al., 2005) . Cyp A, which binds to the HIV-1 CA protein (Luban et al., 1993; Gamble et al., 1996) , meets these criteria. A recent report (Berthoux et al., 2005) , using approaches similar to those employed herein, concluded that Cyp A was required for TRIM5α-mediated restriction of HIV-1 infection (Berthoux et al., 2005) . Our results, which are consistent with those presented by Berthoux et al., suggest that Cyp A enhances but is not absolutely required for the anti-HIV-1 activity of TRIM5α.
We found that blocking the interaction between Cyp A and the HIV-1 CA with the immunosuppressant drug CsA modestly decreased TRIM5α rh antiviral potency. However, in human cells that stably express TRIM5α rh , CsA treatment did not restore the efficiency of HIV-1 infection to levels observed in control cells not expressing TRIM5α rh . TRIM5α hu modestly restricts HIV-1, and the determinants of potency have been mapped to the v1 variable region in the B30.2 domain Stremlau et al., 2005; Yap et al., 2005) . We tested two TRIM5α hu mutants, K324N and R332P, and one human/rhesus TRIM5α chimera, H(R323-332), that have previously been shown to restrict HIV-1 potently . We found that the anti-HIV-1 activities of these TRIM5α hu variants were more dependent on Cyp A function than that of wild-type TRIM5α rh . Thus, one variable that can influence the contribution of Cyp A to restriction is the particular restricting TRIM5α protein.
Capsids from SIV mac and MLV do not bind Cyp A; neither is Cyp A required for efficient replication of these viruses (Franke et al., 1994; Thali et al., 1994; Towers et al., 2003) . We tested whether Cyp A affected restriction of these viruses by TRIM5α. Some slight enhancing effects of CsA treatment on SIV mac Fig. 5 . Rapamycin does not relieve TRIM5α-mediated restriction. HeLa cells transduced with an empty control vector or vectors expressing wild-type TRIM5α rh , wild-type TRIM5α hu , the TRIM5α hu mutants K324N and R332P, or the human/rhesus chimera H(R323-332) were incubated for 2 h in the presence of 0.1% ethanol, 20 nM rapamycin, or 20 nM rapamycin plus 5 μM CsA. The cells were incubated with either 4 kcpm or 32 kcpm of HIV-1-GFP. The percentage of GFP-positive cells was determined by FACS. The experiment was repeated with similar results. Fig. 6 . siRNA knock-down of TRIM5α rh and immunophilins in HIV-1restricted cells. Primary rhesus lung (PRL) cells were either mock-transfected or transfected with 120 nM of the siRNAs targeting the indicated proteins. The cells were then incubated with HIV-1-GFP. The percentage of GFP-positive cells was determined by FACS. The results of a typical experiment are shown. infection were observed, but these were evident in cells that did not express a TRIM5α protein capable of restricting SIV mac infection. Thus, the mild enhancement of SIV mac infection by CsA treatment is apparently independent of TRIM5α-mediated restriction. The ability of TRIM5α to restrict SIV mac and MLV was not specifically dependent on Cyp A function. Certain TRIM5α variants such as TRIM5α hu R332P and TRIM5α sp can restrict infection by both HIV-1 and SIV mac . CsA treatment of cells expressing TRIM5α hu R332P and TRIM5α sp partially relieved the block to HIV-1 infection but had no effect on SIV mac restriction. These results indicate that the contribution of Cyp A to restriction is determined not only by the particular TRIM5α protein but also by the restricted virus.
The interaction between Cyp A and the HIV-1 CA can be disrupted by introducing changes in the Cyp A-binding site of the CA protein (Braaten et al., 1996a (Braaten et al., , 1996b Bukovsky et al., 1997; Franke et al., 1994) . We tested the ability of G89A, a mutant that binds Cyp A much less efficiently than wild-type HIV-1, to escape restriction by wild-type TRIM5α rh or TRIM5α hu variants. There has been some inconsistency in the literature regarding the extent to which HIV-1 CA mutants that cannot bind Cyp A escape restriction by TRIM5α. Some reports indicate that these mutants partially evade restriction in Old World monkey cells (Hatziioannou et al., 2004a; Owens et al., 2004) , whereas one report claims that these mutants are still sensitive to restriction . We found that the G89A change that disrupts Cyp A binding to the HIV-1 CA protein resulted in a virus that was slightly less sensitive to restriction by TRIM5α rh or the TRIM5α hu variants compared with the wild-type virus. Nonetheless, the G89A mutant retained a substantial level of susceptibility to TRIM5αmediated restriction, even in the presence of CsA. Because of the partial nature of this phenotype, the reported differences in the sensitivity of HIV-1 capsid mutants to restriction may be due to differences in the intrinsic level of replication of the HIV-1 CA mutants employed or in the level of TRIM5α expression in the cells. The ability of CsA treatment to relieve HIV-1 restriction by some of the TRIM5α hu variants was diminished for the G89A mutant compared with wild-type HIV-1 (Fig. 3) . This implies that the ability of the restricted virus capsid to bind Cyp A contributes to the Cyp A enhancement of TRIM5αmediated restriction. Our observation that CsA treatment exerts no effect on potent TRIM5α-mediated restriction of SIV mac and N-MLV, which do not interact detectably with Cyp A, supports a model in which Cyp A must bind the viral capsid to act as an auxiliary factor for TRIM5α.
It has been hypothesized that the positive effects of Cyp A on HIV-1 infection involve the prevention of recognition of the HIV-1 capsid by a human antiviral factor Towers et al., 2003) . If this hypothesis is correct, TRIM5α hu is unlikely to be that antiviral factor. We knocked down endogenous TRIM5α hu expression in human cells using siRNA, but did not observe any enhancement of G89A infectivity (data not shown). Furthermore, we expressed TRIM5α hu in canine cells, which lack a TRIM5 gene (Song et al., 2005a) . In these cells, CsA treatment and TRIM5α hu expression independently and additively decreased the infectivity of wild-type HIV-1. The infectivity of the G89A mutant was less than that of the wild-type HIV-1 both in the control cells lacking TRIM5α rh and in the TRIM5α rhexpressing cells. Thus, the positive effects of Cyp A binding to the HIV-1 CA on HIV-1 replication do not depend upon the presence of TRIM5α hu .
The immunophilins, including Cyp A, are members of a large family of conserved proteins. We tested the role of the FK506-binding proteins in TRIM5α rh -mediated HIV-1 restriction by treating restricted cells with rapamycin. Rapamycin, a competitive inhibitor of FK506-binding proteins, did not abrogate restriction in any cell line tested. We also interfered with the expression of several FK506-binding proteins, as well as other members of the cyclophilin family such as cyclophilin M and cyclophilin 40, using siRNA. Disruption of Cyp A expression with siRNA partially relieved HIV-1 restriction in primary rhesus monkey cells; however, none of the siRNA's directed against the other immunophilins tested showed any effects on HIV-1 infectivity in these cells.
Although our results do not support an absolute requirement for Cyp A for TRIM5α-mediated restriction, they do point to a role for Cyp A as an enhancer of TRIM5α activity against viruses like HIV-1 that bind Cyp A. Cyp A appears to be more important for restriction by some TRIM5α variants than by wild-type TRIM5α rh . The mechanism of Cyp A enhancement of TRIM5-mediated restriction requires further investigation. Perhaps the cis/trans-isomerization activity of Cyp A alters the conformation of the HIV-1 CA and exposes a higher-affinity binding surface for TRIM5α. Alternatively, Cyp A might make contacts directly with TRIM5α as part of a ternary complex with CA, thus stabilizing TRIM5α binding. Cyp A may also directly enhance the consequences of TRIM5α binding to the restricted virus capsid, such as accelerated uncoating (Stremlau et al., in press) . Understanding the relationship between Cyp A and TRIM5α hu may be important for developing novel therapies that potentiate the ability of TRIM5α hu to restrict HIV-1.
Materials and methods
Vectors and cell lines
Retroviral vectors encoding rhesus monkey TRIM5α, human TRIM5α, squirrel monkey TRIM5α, African green monkey (Cercopithecus aethiops pygerythrus) TRIM5α, African green monkey (Cercopithecus aethiops tantalus) TRIM5α, and spider monkey TRIM5α were created using the pLPCX vector (Clontech), as previously described (Song et al., 2005a (Song et al., , 2005b Stremlau et al., 2004) . With the exception of TRIM5α rh and TRIM5α hu , the TRIM5α proteins possess N-terminal epitope tags derived from influenza virus hemagglutinin (HA). In the TRIM5α rh and TRIM5α hu constructs, the HA tag is at the C terminus. The human TRIM5α mutants, K324N and R332P, were previously described and contain C-terminal HA tags . A human TRIM5α chimera, H(R323-332), in which residues 323-332 of human TRIM5α have been replaced with the corresponding rhesus monkey TRIM5α residues, was previously described and contains a C-terminal HA tag . Cf2Th canine cells expressing rhesus monkey and human TRIM5α proteins containing C-terminal HA tags were previously described (Javanbakht et al., 2005) . All cell lines were maintained in 1 μg/ml puromycin (Sigma). TE671 cells were purchased from the American Type Culture Collection and maintained as suggested by the supplier.
Infection with viruses expressing green fluorescent protein (GFP)
Recombinant HIV-1, SIV mac , N-MLV, B-MLV, and Moloney MLV (NB-MLV) expressing GFP were prepared as previously described (Hofmann et al., 1999; Perron et al., 2004) . HIV-1 and SIV mac were quantified by measuring reverse transcriptase activity (RT) as described (Li et al., 1992) . N-MLV, B-MLV, and NB-MLV were normalized by serial dilution on 293T cells as previously described . For infections, 4 × 10 4 cells seeded in 24-well plates were incubated for 2 h with 5 μM cyclosporine A (Sigma) or 20 nM rapamycin (Sigma). Virus was added to the cells and allowed to incubate an additional 16 h in the presence of the drug. The cells were washed and returned to culture for 48 h, and then subjected to FACS analysis with a FACScan (Becton Dickinson).
RNA interference
The siRNA 3, which targets rhesus monkey TRIM5α, and the control siRNA were previously described . SmartPool siRNA (Dharmacon) was used to target cyclophilin A (M-004979-00), cyclophilin M (M008888-00), cyclophilin 40 (M-008256-00), FK506-binding protein 2 (M-008945-00), FK506-binding protein 4 (M-006410-01), and FK506-binding protein 5 (M004224-01). Primary rhesus lung (PRL) cells (5 × 10 4 ) (Hofmann et al., 1999) were seeded in sixwell plates and transfected with 120 nM siRNA by using 10 μl of oligofectamine (Invitrogen). After 48 h, the cells were reseeded for infection with HIV-1-GFP, as described above.
